Lucita Van Der Kraan
Overview
Explore the profile of Lucita Van Der Kraan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
70
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kingsmore S, Wright M, Olsen L, Schultz B, Protopsaltis L, Averbuj D, et al.
Am J Hum Genet
. 2024 Dec;
111(12):2643-2667.
PMID: 39642868
Large prospective clinical trials are underway or planned that examine the clinical utility and cost effectiveness of genome-based newborn screening (gNBS). One gNBS platform, BeginNGS, currently screens 53,575 variants for...
2.
Kingsmore S, Wright M, Smith L, Liang Y, Mowrey W, Protopsaltis L, et al.
Am J Hum Genet
. 2024 Dec;
111(12):2618-2642.
PMID: 39642867
Genome-sequence-based newborn screening (gNBS) has substantial potential to improve outcomes in hundreds of severe childhood genetic disorders (SCGDs). However, a major impediment to gNBS is imprecision due to variants classified...
3.
Kingsmore S, Smith L, Kunard C, Bainbridge M, Batalov S, Benson W, et al.
Am J Hum Genet
. 2023 Jun;
110(6):1017.
PMID: 37267897
No abstract available.
4.
Ding Y, Owen M, Le J, Batalov S, Chau K, Kwon Y, et al.
NPJ Genom Med
. 2023 Feb;
8(1):5.
PMID: 36788231
Universal newborn screening (NBS) is a highly successful public health intervention. Archived dried bloodspots (DBS) collected for NBS represent a rich resource for population genomic studies. To fully harness this...
5.
Kingsmore S, Smith L, Kunard C, Bainbridge M, Batalov S, Benson W, et al.
Am J Hum Genet
. 2022 Aug;
109(9):1605-1619.
PMID: 36007526
Newborn screening (NBS) dramatically improves outcomes in severe childhood disorders by treatment before symptom onset. In many genetic diseases, however, outcomes remain poor because NBS has lagged behind drug development....